GlassScriptPhysician profile
Leslie Rose
NPI 1871649400
$10,871.66
in general payments reported to CMS, 2019-2025
40 companies · $2,571 in 2025
The $2,571 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,765 · 2020: $997 · 2021: $688 · 2022: $414 · 2023: $1,740 · 2024: $1,698 · 2025: $2,571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,936 · Education: $71.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,936.47 |
| Education | $71.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,194.25 | 2019-2025 | Otezla, Enbrel, Krystexxa |
| Abbvie INC. | $1,101.41 | 2019-2025 | |
| Pfizer INC. | $1,033.26 | 2019-2025 | |
| Ucb, INC. | $994.93 | 2019-2025 | Bimzelx, Cimzia |
| Astrazeneca Pharmaceuticals LP | $697.07 | 2021-2025 | Saphnelo |
| Inari Medical, INC. | $528.53 | 2021-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Horizon Therapeutics Plc | $471.93 | 2019-2023 | Krystexxa |
| Lilly USA, LLC | $427.35 | 2019-2024 | Taltz |
| Janssen Biotech, INC. | $400.97 | 2019-2025 | Tremfya, Stelara, Remicade |
| Novartis Pharmaceuticals Corporation | $392.55 | 2019-2025 | |
| Glaxosmithkline, LLC. | $376.15 | 2019-2025 | Benlysta |
| Genentech USA, INC. | $353.95 | 2019-2024 | Actemra |
| Cvrx, INC. | $344.36 | 2023 | Barostim Neo System |
| E.R. Squibb & Sons, L.L.C. | $171.96 | 2019-2025 | Orencia |
| Mallinckrodt Enterprises LLC | $156.43 | 2019 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Rose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.